gamma-aminobutyric acid has been researched along with Cognition Disorders in 120 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 9.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "The purpose of this article was to report a case of chorea that developed in an elderly man being treated with gabapentin for severe anxiety." | 7.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "This article reports a case of chorea in an elderly patient who was receiving gabapentin for the treatment of anxiety." | 7.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "Most (74%) had daily seizures that failed multiple drugs (mean, 5)." | 6.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| "Epilepsy was symptomatic in 58%, and 74% exhibited associated cognitive deficits." | 6.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| "Seizures were mixed in nine (47%), and four (21%) manifested Lennox-Gastaut syndrome." | 6.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 6.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| "Chorea is a hyperkinetic movement disorder characterized by irregular, flowing, nonstereotyped, random, involuntary movements." | 5.35 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "On evaluation, the patient had choreiform movements involving the neck, trunk, upper and lower extremities, and tongue." | 5.35 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 5.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumin gamma-aminobutyric acid (GABA) neurons in the disease state." | 4.93 | Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. ( McCarley, RW; McNally, JM, 2016) |
| "To review and summarize the currently available data on the use of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of behavioral and psychological symptoms of dementia (BPSD); to determine whether these medications can be recommended for routine clinical use." | 4.84 | Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. ( Konovalov, S; Muralee, S; Tampi, RR, 2008) |
| "We found lower GABA+/creatine in PD with visual hallucinations (0." | 3.88 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "Maternal thiamine deficiency causes changes in cellular energy metabolism that can interfere with offspring brain development." | 3.76 | Maternal thiamine restriction during lactation induces cognitive impairments and changes in glutamate and GABA concentrations in brain of rat offspring. ( de Freitas-Silva, DM; Franco, GC; Pereira, SR; Resende, Lde S; Ribeiro, AM, 2010) |
| "The purpose of this article was to report a case of chorea that developed in an elderly man being treated with gabapentin for severe anxiety." | 3.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| " In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia." | 3.75 | Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. ( Goto, N; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Kakeda, S; Korogi, Y; Moriya, J; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009) |
| "This article reports a case of chorea in an elderly patient who was receiving gabapentin for the treatment of anxiety." | 3.75 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "Acute administration of the psychotomimetic phencyclidine (PCP) can mimic some features of schizophrenia, while a repeated treatment regimen of PCP may provide a more effective way to model in animals the enduring cognitive dysfunction observed in many schizophrenic patients." | 3.74 | Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. ( Abdul-Monim, Z; Neill, JC; Reynolds, GP, 2007) |
| "All children were diagnosed with cryptogenic epilepsy and symptomatic epilepsy." | 2.80 | [Diagnosis and correction of cognitive impairment in preschool age children with epilepsy]. ( Guzeva, OV; Guzeva, VI; Guzeva, VV; Okhrim, IV; Zgoda, VN, 2015) |
| "Epilepsy was symptomatic in 58%, and 74% exhibited associated cognitive deficits." | 2.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| "Most (74%) had daily seizures that failed multiple drugs (mean, 5)." | 2.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| "Seizures were mixed in nine (47%), and four (21%) manifested Lennox-Gastaut syndrome." | 2.74 | Pregabalin: preliminary experience in intractable childhood epilepsy. ( Alsaihati, BA; Jan, MM; Zuberi, SA, 2009) |
| "Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder." | 2.52 | New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function. ( Kurachi, M; Sumiyoshi, T; Uehara, T, 2015) |
| "The cognitive and motor alterations in hepatic encephalopathy (HE) are the final result of altered neurotransmission and communication between neurons in neuronal networks and circuits." | 2.52 | Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy. ( Agusti, A; Balzano, T; Belghiti, M; Cabrera-Pastor, A; Dadsetan, S; Felipo, V; Garcia-Garcia, R; Gomez-Gimenez, B; Hernandez-Rabaza, V; Llansola, M; Malaguarnera, M; Montoliu, C; Taoro, L, 2015) |
| "Schizophrenia is a disorder of cognitive neurodevelopment." | 2.50 | Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia. ( Lewis, DA, 2014) |
| "Schizophrenia is a brain disorder associated with cognitive deficits that severely affect the patients' capacity for daily functioning." | 2.47 | GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. ( Fish, KN; Gonzalez-Burgos, G; Lewis, DA, 2011) |
| "The incidence of epilepsy is significantly higher in children than adults." | 2.45 | The 2008 Judith Hoyer lecture: epilepsy in children: listening to mothers. ( Holmes, GL, 2009) |
| "In particular, interictal spikes and seizures, especially if prolonged or frequent, may cause acute or long-lasting effects on brain functioning and development, which may impair performance in a variety of behavioral tests." | 2.45 | The epileptic hypothesis: developmentally related arguments based on animal models. ( Galanopoulou, AS; Moshé, SL, 2009) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 2.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| " In this article, we examine issues related to the long-term use of benzodiazepines, including concerns about the development of therapeutic tolerance, dose escalation, and adverse cognitive effects." | 2.43 | Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. ( Pollack, MH; Stevens, JC, 2005) |
| "Parkinson's disease is considered to offer only a limited view of basal ganglia function due to partial striatal depletion of dopamine and the potential involvement of other structures and transmitters in its pathology." | 2.42 | Frontal-striatal circuit functions: context, sequence, and consequence. ( Saint-Cyr, JA, 2003) |
| "Conventional wisdom, and even well-reasoned theoretical mechanisms, suggests that the chronic use of psychoactive substances would impair cognitive functioning of individuals." | 2.42 | Cognitive impairment in substance abuse. ( Cellucci, T; Hedt, J; Jarchow, A; Vik, PW, 2004) |
| " Excitoxins when infused directly into the Nbm destroy non-specifically cell bodies but spare axons passing the injection site, whereas the specificity of AF64A to destroy cholinergic neurons depends on both the dosage applied and the site of injection." | 2.39 | Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. ( Bigl, V; Rossner, S; Schliebs, R, 1996) |
| "To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex." | 1.48 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "We found lower GABA+/creatine in PD with visual hallucinations (0." | 1.48 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
| "Inflammation is considered to be one of the crucial pathological factors associated with the development of Alzheimer's disease, although supportive experimental evidence remains undiscovered." | 1.46 | Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer's disease. ( Abdel-Rahman, E; Ahuja, M; Amin, R; Buabeid, M; Dhanasekaran, M; Majrashi, M; Parameshwaran, K; Pondugula, S; Ramesh, S; Suppiramaniam, V; Thiruchelvan, K, 2017) |
| "Gastrodin treatment also reverted IDPN-induced decreases of γ-aminobutyric acid (GABA) levels and increases of a2 GABAA receptor protein expression in the prefrontal cortex and hippocampus of IDPN-treated rats." | 1.43 | Gastrodin Attenuates Cognitive Deficits Induced by 3,3'-Iminodipropionitrile. ( Jin, X; Li, L; Li, P; Liu, J; Sun, P; Wang, X; Zhang, D, 2016) |
| "Schizophrenia is characterized by anomalous perceptual experiences (e." | 1.39 | Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex. ( Benedek, G; Kelemen, O; Kéri, S; Kiss, I, 2013) |
| "Phencyclidine (PCP) is a noncompetitive NMDA receptor antagonist, and it induces schizophreniform cognitive deficits in healthy humans and similar cognitive deficits in rodents." | 1.37 | GABAergic precursor transplantation into the prefrontal cortex prevents phencyclidine-induced cognitive deficits. ( Kubo, K; Nabeshima, T; Nakajima, K; Tanaka, DH; Toriumi, K, 2011) |
| "We have generated a FTLD-U mouse model (CaMKII-TDP-43 Tg) in which TDP-43 is transgenically overexpressed in the forebrain resulting in phenotypic characteristics mimicking those of FTLD-U." | 1.36 | Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. ( Chien, WL; Cho, KH; Fang, YH; Fu, WM; Lin, CP; Shen, CK; Tsai, KJ; Wang, WT; Wu, TW; Yang, CH, 2010) |
| "On evaluation, the patient had choreiform movements involving the neck, trunk, upper and lower extremities, and tongue." | 1.35 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| "Chorea is a hyperkinetic movement disorder characterized by irregular, flowing, nonstereotyped, random, involuntary movements." | 1.35 | Chorea associated with gabapentin use in an elderly man. ( Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D, 2009) |
| " There is also a fairly broad consensus that gabapentin is safe and well tolerated, but the side-effect profile of gabapentin has not been adequately assessed in pain populations." | 1.33 | Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy. ( Bourin, C; Chen, P; Hogan, JB; Leet, JE; Lindner, MD; Machet, F; McElroy, JF; Stock, DA, 2006) |
| " Amitriptyline did not attenuate STZ-induced mechanical allodynia, even after chronic administration of high doses." | 1.33 | Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy. ( Bourin, C; Chen, P; Hogan, JB; Leet, JE; Lindner, MD; Machet, F; McElroy, JF; Stock, DA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.83) | 18.7374 |
| 1990's | 6 (5.00) | 18.2507 |
| 2000's | 48 (40.00) | 29.6817 |
| 2010's | 64 (53.33) | 24.3611 |
| 2020's | 1 (0.83) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson, SFA | 1 |
| Horst, NK | 1 |
| Horiguchi, N | 1 |
| Roberts, AC | 1 |
| Robbins, TW | 1 |
| Bast, T | 1 |
| Pezze, M | 1 |
| McGarrity, S | 1 |
| Cui, B | 1 |
| Su, D | 1 |
| Li, W | 1 |
| She, X | 1 |
| Zhang, M | 1 |
| Wang, R | 1 |
| Zhai, Q | 1 |
| Firbank, MJ | 1 |
| Parikh, J | 1 |
| Murphy, N | 1 |
| Killen, A | 1 |
| Allan, CL | 1 |
| Collerton, D | 1 |
| Blamire, AM | 1 |
| Taylor, JP | 1 |
| Hu, Y | 1 |
| Liu, M | 1 |
| Liu, P | 1 |
| Yan, JJ | 1 |
| Liu, MY | 1 |
| Zhang, GQ | 1 |
| Zhou, XJ | 1 |
| Yu, BY | 1 |
| Guerrini, G | 1 |
| Ciciani, G | 1 |
| Kelemen, O | 1 |
| Kiss, I | 1 |
| Benedek, G | 1 |
| Kéri, S | 1 |
| Potier, MC | 1 |
| Braudeau, J | 1 |
| Dauphinot, L | 1 |
| Delatour, B | 1 |
| Oulis, P | 1 |
| Kalogerakou, S | 1 |
| Anyfandi, E | 1 |
| Konstantakopoulos, G | 1 |
| Papakosta, VM | 1 |
| Masdrakis, V | 1 |
| Tsaltas, E | 1 |
| Underwood, E | 1 |
| Lewis, DA | 11 |
| Li, CJ | 1 |
| Lu, Y | 1 |
| Zhou, M | 1 |
| Zong, XG | 1 |
| Li, C | 1 |
| Xu, XL | 1 |
| Guo, LJ | 1 |
| Lu, Q | 1 |
| Kimoto, S | 2 |
| Bazmi, HH | 1 |
| Huang, S | 1 |
| Dai, Y | 1 |
| Zhang, Z | 1 |
| Hao, W | 1 |
| Chen, H | 1 |
| Sohal, VS | 1 |
| Abd Allah, ES | 1 |
| Gomaa, AM | 1 |
| Sayed, MM | 1 |
| Salavati, B | 1 |
| Rajji, TK | 1 |
| Price, R | 1 |
| Sun, Y | 1 |
| Graff-Guerrero, A | 1 |
| Daskalakis, ZJ | 1 |
| Pearlman, DM | 1 |
| Najjar, S | 1 |
| Tse, MT | 1 |
| Piantadosi, PT | 1 |
| Floresco, SB | 1 |
| Cohen, EJ | 1 |
| Quarta, E | 1 |
| Fulgenzi, G | 1 |
| Minciacchi, D | 1 |
| Llansola, M | 1 |
| Montoliu, C | 1 |
| Agusti, A | 1 |
| Hernandez-Rabaza, V | 1 |
| Cabrera-Pastor, A | 1 |
| Gomez-Gimenez, B | 1 |
| Malaguarnera, M | 1 |
| Dadsetan, S | 1 |
| Belghiti, M | 1 |
| Garcia-Garcia, R | 1 |
| Balzano, T | 1 |
| Taoro, L | 1 |
| Felipo, V | 1 |
| Laurent, C | 1 |
| Burnouf, S | 1 |
| Ferry, B | 1 |
| Batalha, VL | 1 |
| Coelho, JE | 1 |
| Baqi, Y | 1 |
| Malik, E | 1 |
| Mariciniak, E | 1 |
| Parrot, S | 1 |
| Van der Jeugd, A | 1 |
| Faivre, E | 1 |
| Flaten, V | 1 |
| Ledent, C | 1 |
| D'Hooge, R | 1 |
| Sergeant, N | 1 |
| Hamdane, M | 1 |
| Humez, S | 1 |
| Müller, CE | 1 |
| Lopes, LV | 1 |
| Buée, L | 1 |
| Blum, D | 1 |
| Chutko, LS | 1 |
| Surushkina, SIu | 1 |
| Iakovenko, EA | 1 |
| Nikishena, IS | 1 |
| Anisimova, TI | 1 |
| Bondarchuk, IuL | 1 |
| Rowland, LM | 1 |
| Krause, BW | 1 |
| Wijtenburg, SA | 1 |
| McMahon, RP | 1 |
| Chiappelli, J | 1 |
| Nugent, KL | 1 |
| Nisonger, SJ | 1 |
| Korenic, SA | 1 |
| Kochunov, P | 1 |
| Hong, LE | 1 |
| Powell, SB | 1 |
| Khan, A | 1 |
| Young, JW | 1 |
| Scott, CN | 1 |
| Buell, MR | 1 |
| Caldwell, S | 1 |
| Tsan, E | 1 |
| de Jong, LA | 1 |
| Acheson, DT | 1 |
| Lucero, J | 1 |
| Geyer, MA | 1 |
| Behrens, MM | 1 |
| Aoyama, Y | 1 |
| Toriumi, K | 2 |
| Mouri, A | 1 |
| Hattori, T | 1 |
| Ueda, E | 1 |
| Shimato, A | 1 |
| Sakakibara, N | 1 |
| Soh, Y | 1 |
| Mamiya, T | 1 |
| Nagai, T | 1 |
| Kim, HC | 1 |
| Hiramatsu, M | 1 |
| Nabeshima, T | 2 |
| Yamada, K | 1 |
| Lipina, TV | 1 |
| Prasad, T | 1 |
| Yokomaku, D | 1 |
| Luo, L | 1 |
| Connor, SA | 1 |
| Kawabe, H | 1 |
| Wang, YT | 1 |
| Brose, N | 1 |
| Roder, JC | 1 |
| Craig, AM | 1 |
| Sawano, E | 1 |
| Iwatani, K | 1 |
| Tominaga-Yoshino, K | 1 |
| Ogura, A | 1 |
| Tashiro, T | 1 |
| Terada, T | 1 |
| Kakimoto, A | 1 |
| Yoshikawa, E | 1 |
| Kono, S | 1 |
| Bunai, T | 1 |
| Hosoi, Y | 1 |
| Sakao-Suzuki, M | 1 |
| Konishi, T | 1 |
| Miyajima, H | 1 |
| Ouchi, Y | 1 |
| Solas, M | 1 |
| Puerta, E | 1 |
| Ramirez, MJ | 2 |
| Datusalia, AK | 1 |
| Sharma, SS | 1 |
| Guzeva, VI | 1 |
| Guzeva, VV | 1 |
| Guzeva, OV | 1 |
| Okhrim, IV | 1 |
| Zgoda, VN | 1 |
| Long, Q | 1 |
| Hei, Y | 1 |
| Luo, Q | 1 |
| Tian, Y | 1 |
| Yang, J | 1 |
| Li, J | 1 |
| Wei, L | 1 |
| Liu, W | 1 |
| Uehara, T | 1 |
| Sumiyoshi, T | 1 |
| Kurachi, M | 1 |
| Izumi, Y | 1 |
| Zorumski, CF | 1 |
| Wang, X | 1 |
| Li, P | 1 |
| Liu, J | 1 |
| Jin, X | 1 |
| Li, L | 1 |
| Zhang, D | 1 |
| Sun, P | 1 |
| McNally, JM | 1 |
| McCarley, RW | 1 |
| Smulevich, AB | 1 |
| Volel, BA | 1 |
| Ternovaya, ES | 1 |
| Nikitina, YM | 1 |
| Ladrón de Guevara-Miranda, D | 1 |
| Millón, C | 1 |
| Rosell-Valle, C | 1 |
| Pérez-Fernández, M | 1 |
| Missiroli, M | 1 |
| Serrano, A | 1 |
| Pavón, FJ | 1 |
| Rodríguez de Fonseca, F | 1 |
| Martínez-Losa, M | 1 |
| Álvarez-Dolado, M | 1 |
| Santín, LJ | 1 |
| Castilla-Ortega, E | 1 |
| Ahuja, M | 1 |
| Buabeid, M | 1 |
| Abdel-Rahman, E | 1 |
| Majrashi, M | 1 |
| Parameshwaran, K | 1 |
| Amin, R | 1 |
| Ramesh, S | 1 |
| Thiruchelvan, K | 1 |
| Pondugula, S | 1 |
| Suppiramaniam, V | 1 |
| Dhanasekaran, M | 1 |
| Jan, MM | 1 |
| Zuberi, SA | 1 |
| Alsaihati, BA | 1 |
| Striano, S | 1 |
| Striano, P | 1 |
| Coppola, A | 1 |
| Romanelli, P | 1 |
| Freund, HJ | 1 |
| Kuhn, J | 1 |
| Lenartz, D | 1 |
| Mai, JK | 1 |
| Schnell, T | 1 |
| Klosterkoetter, J | 1 |
| Sturm, V | 1 |
| Lyoo, IK | 1 |
| Yoon, SJ | 1 |
| Musen, G | 1 |
| Simonson, DC | 1 |
| Weinger, K | 1 |
| Bolo, N | 1 |
| Ryan, CM | 1 |
| Kim, JE | 1 |
| Renshaw, PF | 1 |
| Jacobson, AM | 1 |
| Galanopoulou, AS | 1 |
| Moshé, SL | 1 |
| Holmes, GL | 1 |
| Attupurath, R | 1 |
| Aziz, R | 1 |
| Wollman, D | 1 |
| Muralee, S | 2 |
| Tampi, RR | 2 |
| Ochalski, PG | 1 |
| Fellows-Mayle, W | 1 |
| Hsieh, LB | 1 |
| Srinivas, R | 1 |
| Okonkwo, DO | 1 |
| Dixon, CE | 1 |
| Adelson, PD | 1 |
| Goto, N | 1 |
| Yoshimura, R | 1 |
| Kakeda, S | 1 |
| Moriya, J | 1 |
| Hayashi, K | 1 |
| Ikenouchi-Sugita, A | 1 |
| Umene-Nakano, W | 1 |
| Hori, H | 1 |
| Ueda, N | 1 |
| Korogi, Y | 1 |
| Nakamura, J | 1 |
| Blake, MG | 1 |
| Boccia, MM | 1 |
| Carcaboso, AM | 1 |
| Chiappetta, DA | 1 |
| Höcht, C | 1 |
| Krawczyk, MC | 1 |
| Sosnik, A | 1 |
| Baratti, CM | 1 |
| Cavanna, AE | 1 |
| Ali, F | 1 |
| Rickards, HE | 1 |
| McCorry, D | 1 |
| Salinsky, M | 1 |
| Storzbach, D | 2 |
| Munoz, S | 1 |
| de Freitas-Silva, DM | 1 |
| Resende, Lde S | 1 |
| Pereira, SR | 1 |
| Franco, GC | 1 |
| Ribeiro, AM | 1 |
| Ji, G | 1 |
| Sun, H | 1 |
| Fu, Y | 1 |
| Li, Z | 1 |
| Pais-Vieira, M | 1 |
| Galhardo, V | 1 |
| Neugebauer, V | 1 |
| Tsai, KJ | 1 |
| Yang, CH | 1 |
| Fang, YH | 1 |
| Cho, KH | 1 |
| Chien, WL | 1 |
| Wang, WT | 1 |
| Wu, TW | 1 |
| Lin, CP | 1 |
| Fu, WM | 1 |
| Shen, CK | 1 |
| Rubenstein, JL | 1 |
| Mikhaĭlova, NA | 1 |
| Kamchatov, PR | 1 |
| Fujiwara, H | 1 |
| Zheng, M | 1 |
| Miyamoto, A | 1 |
| Hoshino, O | 1 |
| Braden, BB | 1 |
| Garcia, AN | 1 |
| Mennenga, SE | 1 |
| Prokai, L | 1 |
| Villa, SR | 1 |
| Acosta, JI | 1 |
| Lefort, N | 1 |
| Simard, AR | 1 |
| Bimonte-Nelson, HA | 1 |
| Curley, AA | 2 |
| Arion, D | 1 |
| Volk, DW | 4 |
| Asafu-Adjei, JK | 1 |
| Sampson, AR | 1 |
| Fish, KN | 2 |
| Goldman, D | 1 |
| Kim, DH | 2 |
| Park, SJ | 1 |
| Kim, JM | 1 |
| Jeon, SJ | 1 |
| Cho, YW | 1 |
| Son, KH | 1 |
| Lee, HJ | 1 |
| Moon, JH | 1 |
| Cheong, JH | 1 |
| Ko, KH | 1 |
| Ryu, JH | 1 |
| Gonzalez-Burgos, G | 1 |
| Tanaka, DH | 1 |
| Kubo, K | 1 |
| Nakajima, K | 1 |
| Mease, PJ | 1 |
| Dundon, K | 1 |
| Sarzi-Puttini, P | 1 |
| Glausier, JR | 1 |
| Stan, AD | 1 |
| Fatemi, SH | 1 |
| Aldinger, KA | 1 |
| Ashwood, P | 1 |
| Bauman, ML | 1 |
| Blaha, CD | 1 |
| Blatt, GJ | 1 |
| Chauhan, A | 1 |
| Chauhan, V | 1 |
| Dager, SR | 1 |
| Dickson, PE | 1 |
| Estes, AM | 1 |
| Goldowitz, D | 1 |
| Heck, DH | 1 |
| Kemper, TL | 1 |
| King, BH | 1 |
| Martin, LA | 1 |
| Millen, KJ | 1 |
| Mittleman, G | 1 |
| Mosconi, MW | 1 |
| Persico, AM | 1 |
| Sweeney, JA | 1 |
| Webb, SJ | 1 |
| Welsh, JP | 1 |
| Femenía, T | 1 |
| Gómez-Galán, M | 1 |
| Lindskog, M | 1 |
| Magara, S | 1 |
| Grégoire, S | 1 |
| Michaud, V | 1 |
| Chapuy, E | 1 |
| Eschalier, A | 1 |
| Ardid, D | 1 |
| Sun, X | 1 |
| Meng, X | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Wang, L | 1 |
| Qin, X | 1 |
| Sui, N | 1 |
| Zhang, Y | 1 |
| Tiurenkov, IN | 1 |
| Bagmetova, VV | 1 |
| Borodkina, LE | 1 |
| Berestovitskaia, VM | 1 |
| Vasil'eva, OS | 1 |
| Geffen, Y | 1 |
| Keefe, R | 1 |
| Rabinowitz, J | 1 |
| Anand, R | 1 |
| Davidson, M | 1 |
| Saint-Cyr, JA | 1 |
| Morrow, BA | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Joffe, H | 1 |
| Soares, CN | 1 |
| Cohen, LS | 1 |
| Ito, H | 1 |
| Kusaka, H | 1 |
| Sparkes, SJ | 1 |
| MacMaster, FP | 1 |
| Carrey, NC | 1 |
| Vik, PW | 1 |
| Cellucci, T | 1 |
| Jarchow, A | 1 |
| Hedt, J | 1 |
| Holsen, L | 1 |
| Thompson, T | 1 |
| O'Donnell, BF | 1 |
| Hetrick, WP | 1 |
| Vohs, JL | 1 |
| Krishnan, GP | 1 |
| Carroll, CA | 1 |
| Shekhar, A | 1 |
| Cruz, D | 1 |
| Eggan, S | 1 |
| Erickson, S | 1 |
| Tamminga, C | 1 |
| Hashimoto, T | 1 |
| Tisch, S | 1 |
| Silberstein, P | 1 |
| Limousin-Dowsey, P | 1 |
| Jahanshahi, M | 1 |
| Salinsky, MC | 1 |
| Spencer, DC | 1 |
| Oken, BS | 1 |
| Landry, T | 1 |
| Dodrill, CB | 1 |
| Stevens, JC | 1 |
| Pollack, MH | 1 |
| Ameli, R | 1 |
| Snow, J | 1 |
| Rakocevic, G | 1 |
| Dalakas, MC | 1 |
| Garcia-Alloza, M | 1 |
| Tsang, SW | 1 |
| Gil-Bea, FJ | 1 |
| Francis, PT | 1 |
| Lai, MK | 1 |
| Marcos, B | 1 |
| Chen, CP | 1 |
| Horvath, J | 1 |
| Coeytaux, A | 1 |
| Jallon, P | 1 |
| Landis, T | 1 |
| Temperli, P | 1 |
| Burkhard, PR | 1 |
| Aharonovich, E | 1 |
| Hasin, DS | 1 |
| Brooks, AC | 1 |
| Liu, X | 1 |
| Bisaga, A | 1 |
| Nunes, EV | 1 |
| Comery, TA | 1 |
| Martone, RL | 1 |
| Aschmies, S | 1 |
| Atchison, KP | 1 |
| Diamantidis, G | 1 |
| Gong, X | 1 |
| Zhou, H | 1 |
| Kreft, AF | 1 |
| Pangalos, MN | 1 |
| Sonnenberg-Reines, J | 1 |
| Jacobsen, JS | 1 |
| Marquis, KL | 1 |
| Birzniece, V | 1 |
| Bäckström, T | 1 |
| Johansson, IM | 1 |
| Lindblad, C | 1 |
| Lundgren, P | 1 |
| Löfgren, M | 1 |
| Olsson, T | 1 |
| Ragagnin, G | 1 |
| Taube, M | 1 |
| Turkmen, S | 1 |
| Wahlström, G | 1 |
| Wang, MD | 1 |
| Wihlbäck, AC | 1 |
| Zhu, D | 1 |
| Woo, NH | 1 |
| Lu, B | 1 |
| Lindner, MD | 1 |
| Bourin, C | 1 |
| Chen, P | 1 |
| McElroy, JF | 1 |
| Leet, JE | 1 |
| Hogan, JB | 1 |
| Stock, DA | 1 |
| Machet, F | 1 |
| Lanctôt, KL | 1 |
| Herrmann, N | 1 |
| Rothenburg, L | 1 |
| Eryavec, G | 1 |
| Moghaddam, B | 1 |
| Povedano, M | 1 |
| Gascón, J | 1 |
| Gálvez, R | 1 |
| Ruiz, M | 1 |
| Rejas, J | 1 |
| Menzies, L | 1 |
| Ooi, C | 1 |
| Kamath, S | 1 |
| Suckling, J | 1 |
| McKenna, P | 1 |
| Fletcher, P | 1 |
| Bullmore, E | 1 |
| Stephenson, C | 1 |
| Abdul-Monim, Z | 1 |
| Neill, JC | 1 |
| Reynolds, GP | 1 |
| van der Stelt, O | 1 |
| Belger, A | 1 |
| Lombroso, CT | 1 |
| Palop, JJ | 1 |
| Chin, J | 1 |
| Roberson, ED | 1 |
| Wang, J | 1 |
| Thwin, MT | 1 |
| Bien-Ly, N | 1 |
| Yoo, J | 1 |
| Ho, KO | 1 |
| Yu, GQ | 1 |
| Kreitzer, A | 1 |
| Finkbeiner, S | 1 |
| Noebels, JL | 1 |
| Mucke, L | 1 |
| Konovalov, S | 1 |
| Owen, RT | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Martínez-Cué, C | 1 |
| Baillieux, H | 1 |
| Verslegers, W | 1 |
| Paquier, P | 1 |
| De Deyn, PP | 1 |
| Mariën, P | 1 |
| Petty, F | 1 |
| Davis, LL | 1 |
| Kabel, D | 1 |
| Kramer, GL | 1 |
| Schliebs, R | 1 |
| Rossner, S | 1 |
| Bigl, V | 1 |
| Leach, JP | 1 |
| Girvan, J | 1 |
| Paul, A | 1 |
| Brodie, MJ | 1 |
| Joseph, JA | 1 |
| Shukitt-Hale, B | 1 |
| Denisova, NA | 1 |
| Prior, RL | 1 |
| Cao, G | 1 |
| Martin, A | 1 |
| Taglialatela, G | 1 |
| Bickford, PC | 1 |
| Martin, R | 2 |
| Kuzniecky, R | 2 |
| Ho, S | 1 |
| Hetherington, H | 1 |
| Pan, J | 1 |
| Sinclair, K | 2 |
| Gilliam, F | 2 |
| Faught, E | 2 |
| Heim, C | 1 |
| Lan, J | 1 |
| Sieklucka, M | 1 |
| Kurz, T | 1 |
| Riederer, P | 1 |
| Gerlach, M | 1 |
| Sontag, KH | 1 |
| Meador, K | 1 |
| Turrentine, L | 1 |
| Aldenkamp, AP | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Makeeva, VL | 1 |
| Watanabe, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| Simultaneous Deep Brain Stimulation of the Globus Pallidus Internus and the Nucleus Basalis of Meynert in Patients With Parkinson's Disease and Mild Cognitive Impairment[NCT05320523] | 10 participants (Anticipated) | Interventional | 2021-07-20 | Recruiting | |||
| Modulation of the Activity in the Cerebellum With Transcranial Direct Current Stimulation in Autistic Participants[NCT05781412] | 100 participants (Anticipated) | Interventional | 2022-05-24 | Recruiting | |||
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Treatment of Crack-cocaine Addiction Through Cognitive Neuromodulation of the Prefrontal Cortex Produced by Transcranial Direct Current Stimulation.[NCT01337297] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Neural Mechanistic Explanations for Differential Drug Abuse Treatment Outcomes[NCT01678833] | 7 participants (Actual) | Observational | 2012-07-19 | Completed | |||
| Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758] | Phase 2 | 96 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702] | Phase 2 | 65 participants (Anticipated) | Interventional | 2020-01-31 | Not yet recruiting | ||
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
abstinence to the use of crack-cocaine up to 3 months after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS. (NCT01337297)
Timeframe: Two days after the end of tDCS treatment (one session every other day, 5 sessions), that is, on the 12nd day from the beginning.
| Intervention | percentage of participants (Number) |
|---|---|
| Active-tDCS | 71.4 |
| Sham-tDCS | 16.6 |
Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks
| Intervention | percent correct recalled (Mean) |
|---|---|
| aMCI_62.5 | 38 |
| aMCI_62.5 Placebo | 33 |
| aMCI_125 | 33 |
| aMCI_125 Placebo | 28 |
| aMCI_250 | 34 |
| aMCI_250 Placebo | 31 |
| Age Matched Control | 44 |
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks
| Intervention | mean beta coefficient (Mean) |
|---|---|
| aMCI_62.5 | -0.1203 |
| aMCI_62.5 Placebo | 0.4353 |
| aMCI_125 | -0.2238 |
| aMCI_125 Placebo | 0.8814 |
| aMCI_250 | 0.3928 |
| aMCI_250 Placebo | 0.4825 |
| Age Matched Control | -.02507 |
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
40 reviews available for gamma-aminobutyric acid and Cognition Disorders
| Article | Year |
|---|---|
Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Hippocampus; Humans; Mental Disorders; Neural | 2017 |
Benzodiazepine receptor ligands: a patent review (2006-2012).
Topics: Animals; Binding Sites; Cognition Disorders; Drug Design; gamma-Aminobutyric Acid; Humans; Ligands; | 2013 |
Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down Syndrome; GABA Agents; gamma-Aminobutyric | 2014 |
Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia.
Topics: Cerebral Cortex; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Nerve Net; Neural Inhibition; | 2014 |
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
Topics: Brain; Cognition Disorders; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Long-Term Pote | 2015 |
Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Prefrontal Cortex; Schizophrenia; Sig | 2015 |
Acetylcholine, GABA and neuronal networks: a working hypothesis for compensations in the dystrophic brain.
Topics: Acetylcholine; Animals; Brain; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Muscular Dystro | 2015 |
Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Hepatic Encephalopathy; Humans | 2015 |
Treatment Options in Alzheimer´s Disease: The GABA Story.
Topics: Aged; Alzheimer Disease; Animals; Cognition Disorders; Drug Design; gamma-Aminobutyric Acid; Humans; | 2015 |
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Psychotropic Drugs; Receptor, Seroton | 2015 |
Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neurons; Parvalbumins; Psychotic Diso | 2016 |
The syndrome gelastic seizures-hypothalamic hamartoma: severe, potentially reversible encephalopathy.
Topics: Brain Neoplasms; Cognition Disorders; Epilepsies, Partial; gamma-Aminobutyric Acid; Hamartoma; Hypot | 2009 |
The epileptic hypothesis: developmentally related arguments based on animal models.
Topics: Age Factors; Animals; Brain; Child, Preschool; Cognition Disorders; Developmental Disabilities; Dise | 2009 |
The 2008 Judith Hoyer lecture: epilepsy in children: listening to mothers.
Topics: Animals; Anticonvulsants; Brain; Child; Cognition Disorders; Epilepsy; gamma-Aminobutyric Acid; Huma | 2009 |
Behavioral and cognitive effects of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan | 2010 |
Annual Research Review: Development of the cerebral cortex: implications for neurodevelopmental disorders.
Topics: Affective Symptoms; Animals; Autistic Disorder; Axons; Body Patterning; Brain Mapping; Cerebral Cort | 2011 |
GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia.
Topics: Animals; Biological Clocks; Cerebral Cortex; Cognition Disorders; Cortical Synchronization; Disease | 2011 |
Pharmacotherapy of fibromyalgia.
Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine H | 2011 |
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia.
Topics: Cognition Disorders; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Interneurons; Parvalbumins; | 2012 |
Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Prefrontal Cort | 2012 |
Consensus paper: pathological role of the cerebellum in autism.
Topics: Animals; Autistic Disorder; Cell Adhesion Molecules, Neuronal; Cerebellar Diseases; Cerebellum; Cogn | 2012 |
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
Topics: Animals; Antidepressive Agents; Behavioral Symptoms; Cognition Disorders; gamma-Aminobutyric Acid; G | 2012 |
Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction.
Topics: Cognition Disorders; gamma-Aminobutyric Acid; Gene Expression Regulation; Humans; Nerve Net; Prefron | 2002 |
Frontal-striatal circuit functions: context, sequence, and consequence.
Topics: Basal Ganglia; Cognition Disorders; Corpus Striatum; Dopamine; Frontal Lobe; gamma-Aminobutyric Acid | 2003 |
Assessment and treatment of hot flushes and menopausal mood disturbance.
Topics: Acetates; Aging; Amines; Anti-Anxiety Agents; Cognition Disorders; Cyclohexanecarboxylic Acids; Fema | 2003 |
[Cognitive impairment induced by sedatives/hypnotics].
Topics: Aged; Benzodiazepines; Cognition Disorders; Female; gamma-Aminobutyric Acid; Humans; Hypnotics and S | 2004 |
Cognitive impairment in substance abuse.
Topics: Alcohol Amnestic Disorder; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Eth | 2004 |
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia.
Topics: Adolescent; Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neural | 2004 |
The basal ganglia: anatomy, physiology, and pharmacology.
Topics: Acetylcholine; Basal Ganglia; Cognition Disorders; Corpus Striatum; Frontal Lobe; gamma-Aminobutyric | 2004 |
Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Cogn | 2005 |
Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems.
Topics: Animals; Brain; Cognition; Cognition Disorders; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; H | 2006 |
Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders.
Topics: Animals; Central Nervous System Diseases; Cerebral Cortex; Cognition Disorders; gamma-Aminobutyric A | 2006 |
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neural Inhibition; Pre | 2006 |
Application of electroencephalography to the study of cognitive and brain functions in schizophrenia.
Topics: Catechol O-Methyltransferase; Cognition Disorders; Electroencephalography; Event-Related Potentials, | 2007 |
Neonatal seizures: gaps between the laboratory and the clinic.
Topics: Animals; Brain; Cognition Disorders; Cohort Studies; Disease Models, Animal; Electroencephalography; | 2007 |
Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review.
Topics: Aggression; Amines; Anticonvulsants; Carbamazepine; Cognition Disorders; Cyclohexanecarboxylic Acids | 2008 |
Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Depression; Fatigue; Fibromyalgia; gamma-Am | 2007 |
Serotonin dysfunction disorders: a behavioral neurochemistry perspective.
Topics: Animals; Antidepressive Agents; Anxiety Disorders; Behavior, Animal; Brain Chemistry; Cognition Diso | 1996 |
Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Antibodies, Monoclonal; Cerebral Co | 1996 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
11 trials available for gamma-aminobutyric acid and Cognition Disorders
| Article | Year |
|---|---|
[Diagnosis and correction of cognitive impairment in preschool age children with epilepsy].
Topics: Child; Child, Preschool; Cognition Disorders; Electroencephalography; Epilepsy; Female; gamma-Aminob | 2015 |
[Pantogam activ (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Anxiety Disorders; Blood Pressure Monitoring, Ambu | 2015 |
Pregabalin: preliminary experience in intractable childhood epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Drug Therapy, Combination | 2009 |
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation.
Topics: Acetylcholine; Aged; Arousal; Attention; Basal Nucleus of Meynert; Cholinergic Fibers; Cognition; Co | 2009 |
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation.
Topics: Acetylcholine; Aged; Arousal; Attention; Basal Nucleus of Meynert; Cholinergic Fibers; Cognition; Co | 2009 |
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation.
Topics: Acetylcholine; Aged; Arousal; Attention; Basal Nucleus of Meynert; Cholinergic Fibers; Cognition; Co | 2009 |
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation.
Topics: Acetylcholine; Aged; Arousal; Attention; Basal Nucleus of Meynert; Cholinergic Fibers; Cognition; Co | 2009 |
Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial.
Topics: Adult; Affect; Anticonvulsants; Cognition; Cognition Disorders; Double-Blind Method; Female; gamma-A | 2010 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers.
Topics: Activities of Daily Living; Adult; Amines; Anticonvulsants; Brain; Cognition; Cognition Disorders; C | 2005 |
Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.
Topics: Adult; Brain; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Flumazenil; GABA Modulators | 2007 |
Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analysis of Variance; Anticonvulsants; Cognition Disorder | 1997 |
Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.
Topics: Acetates; Adult; Affect; Amines; Anticonvulsants; Cognition Disorders; Cyclohexanecarboxylic Acids; | 1999 |
Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults.
Topics: Acetates; Age Factors; Aged; Amines; Anticonvulsants; Attention; Carbamazepine; Cognition; Cognition | 2001 |
69 other studies available for gamma-aminobutyric acid and Cognition Disorders
| Article | Year |
|---|---|
Flexible versus Fixed Spatial Self-Ordered Response Sequencing: Effects of Inactivation and Neurochemical Modulation of Ventrolateral Prefrontal Cortex.
Topics: Animals; Antipsychotic Agents; Baclofen; Callithrix; Cognition Disorders; Dopamine; Dopamine D2 Rece | 2021 |
Effects of chronic noise exposure on the microbiome-gut-brain axis in senescence-accelerated prone mice: implications for Alzheimer's disease.
Topics: Aging; Animals; Avoidance Learning; Brain; Claudins; Cognition Disorders; Corticosterone; Cytokines; | 2018 |
Reduced occipital GABA in Parkinson disease with visual hallucinations.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Creatine; Female; gamma-Aminobutyric Acid; Gray Matter | 2018 |
Effect of kai xin san on learning and memory in a rat model of paradoxical sleep deprivation.
Topics: Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Cognition Disorders; Cyclic AMP | 2013 |
Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Contrast Sensiti | 2013 |
Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence.
Topics: Benzodiazepines; Central Nervous System Agents; Cognition; Cognition Disorders; Female; Follow-Up St | 2014 |
Can Down syndrome be treated?
Topics: Adult; Animals; Brain; Child; Chromosomes, Human, Pair 21; Clinical Trials as Topic; Cognition Disor | 2014 |
Activation of GABAB receptors ameliorates cognitive impairment via restoring the balance of HCN1/HCN2 surface expression in the hippocampal CA1 area in rats with chronic cerebral hypoperfusion.
Topics: Animals; CA1 Region, Hippocampal; Cognition Disorders; gamma-Aminobutyric Acid; Hyperpolarization-Ac | 2014 |
Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268.
Topics: Adult; Animals; Antipsychotic Agents; Autopsy; Cognition Disorders; Confounding Factors, Epidemiolog | 2014 |
Docosahexaenoic acid intake ameliorates ketamine-induced impairment of spatial cognition and learning ability in ICR mice.
Topics: Animals; Cognition; Cognition Disorders; Docosahexaenoic Acids; gamma-Aminobutyric Acid; Hippocampus | 2014 |
Identifying pathways leading to prefrontal GABA-ergic interneuron dysfunction in schizophrenia.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
The effect of omega-3 on cognition in hypothyroid adult male rats.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Calcium Channels, L-Type; Carbimazole; Cognition; Co | 2014 |
Neuroinflammation versus decreased Zif268 mRNA expression as causal mediators of decreased GAD67 mRNA expression within dorsolateral prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
Response to Pearlman and Najjar.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Animals; Cognition Disorders; Disease Models, | 2016 |
[Cognitive and emotional impairments in patients with protracted anxiety-phobic disorders].
Topics: Acute Disease; Adolescent; Adult; Chronic Disease; Cognition Disorders; gamma-Aminobutyric Acid; Hum | 2014 |
Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study.
Topics: Adult; Age Factors; Case-Control Studies; Cognition Disorders; Female; Frontal Lobe; gamma-Aminobuty | 2016 |
Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats.
Topics: Age Factors; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Female; gamma-A | 2015 |
Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex.
Topics: Animals; Cell Cycle; Cell Movement; Cognition Disorders; Disease Models, Animal; Female; gamma-Amino | 2016 |
Cognitive Deficits in Calsyntenin-2-deficient Mice Associated with Reduced GABAergic Transmission.
Topics: Animals; Brain; Calcium-Binding Proteins; Cognition Disorders; Exploratory Behavior; Female; Fluores | 2016 |
Reduction in NPY-positive neurons and dysregulation of excitability in young senescence-accelerated mouse prone 8 (SAMP8) hippocampus precede the onset of cognitive impairment.
Topics: Aging; Animals; Behavior, Animal; Cognition Disorders; Cyclic AMP Response Element-Binding Protein; | 2015 |
The Possible Link between GABAergic Dysfunction and Cognitive Decline in a Patient with Idiopathic Hypoparathyroidism.
Topics: Aged; Basal Ganglia; Brain; Calcinosis; Cerebellum; Cerebral Cortex; Cognition; Cognition Disorders; | 2015 |
NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway.
Topics: Animals; Avoidance Learning; Blood Glucose; Brain; Cognition Disorders; CREB-Binding Protein; Diabet | 2016 |
BMSCs transplantation improves cognitive impairment via up-regulation of hippocampal GABAergic system in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Bone Marrow Transplantation; Brain Ischemia; Carotid Artery Diseases; Cell Movement; Chroni | 2015 |
GABA and Endocannabinoids Mediate Depotentiation of Schaffer Collateral Synapses Induced by Stimulation of Temperoammonic Inputs.
Topics: Animals; Brain; CA1 Region, Hippocampal; Calcium Channels, L-Type; Cognition Disorders; Endocannabin | 2016 |
Gastrodin Attenuates Cognitive Deficits Induced by 3,3'-Iminodipropionitrile.
Topics: Animals; Benzyl Alcohols; Cognition Disorders; gamma-Aminobutyric Acid; Gastrodia; Glucosides; Hippo | 2016 |
Long-lasting memory deficits in mice withdrawn from cocaine are concomitant with neuroadaptations in hippocampal basal activity, GABAergic interneurons and adult neurogenesis.
Topics: Adaptation, Physiological; Aging; Animals; Behavior, Animal; Cocaine; Cognition Disorders; Dentate G | 2017 |
Immunological alteration & toxic molecular inductions leading to cognitive impairment & neurotoxicity in transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognition D | 2017 |
Altered prefrontal glutamate-glutamine-gamma-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus.
Topics: Adult; Cognition Disorders; Depression; Diabetes Mellitus, Type 1; Female; gamma-Aminobutyric Acid; | 2009 |
Chorea associated with gabapentin use in an elderly man.
Topics: Aged; Amines; Analgesics; Anti-Dyskinesia Agents; Anxiety; Chorea; Cognition Disorders; Cyclohexanec | 2009 |
Flumazenil administration attenuates cognitive impairment in immature rats after controlled cortical impact.
Topics: Animals; Brain; Brain Chemistry; Brain Injuries; Cognition Disorders; Disease Models, Animal; Dose-R | 2010 |
Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition Disorders; Fem | 2009 |
Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in mice.
Topics: Amines; Animals; Anticonvulsants; Cognition Disorders; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
Maternal thiamine restriction during lactation induces cognitive impairments and changes in glutamate and GABA concentrations in brain of rat offspring.
Topics: Analysis of Variance; Animals; Animals, Suckling; Brain; Cognition Disorders; Energy Metabolism; Fem | 2010 |
Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation.
Topics: Amygdala; Animals; Arthritis; Cognition Disorders; Decision Making; Disease Models, Animal; gamma-Am | 2010 |
Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U.
Topics: Animals; Apoptosis; Atrophy; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Caspase 3; C | 2010 |
[The use of pantogam in patients with moderate cognitive disorders of vascular genesis].
Topics: Aged; Cerebrovascular Disorders; Cognition Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; | 2009 |
Insufficient augmentation of ambient GABA responsible for age-related cognitive deficit.
Topics: Aging; Cognition Disorders; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Humans | 2011 |
Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time.
Topics: Animals; Cognition Disorders; Contraceptive Agents, Female; Female; gamma-Aminobutyric Acid; Glutama | 2011 |
Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.
Topics: Adult; Blotting, Western; Cognition Disorders; Cohort Studies; Female; gamma-Aminobutyric Acid; Glut | 2011 |
Molecular etiologies of schizophrenia: are we almost there yet?
Topics: Cognition Disorders; Endophenotypes; Female; gamma-Aminobutyric Acid; Genetic Association Studies; G | 2011 |
Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B.
Topics: Amyloid beta-Peptides; Animals; Animals, Newborn; Benzofurans; Cholinergic Antagonists; Cholinestera | 2011 |
GABAergic precursor transplantation into the prefrontal cortex prevents phencyclidine-induced cognitive deficits.
Topics: Animals; Animals, Newborn; Cognition Disorders; Embryonic Stem Cells; Female; gamma-Aminobutyric Aci | 2011 |
Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin.
Topics: Affective Symptoms; Amines; Analgesics; Animals; Antidepressive Agents; Cognition; Cognition Disorde | 2012 |
GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Animals, Newborn; Cells, Cultured; C | 2012 |
[Fenibut and its citrate prevent psychoneurological disorders caused by chronic stress (paradoxical sleep deprivation)].
Topics: Adrenal Glands; Animals; Avoidance Learning; Behavior, Animal; Citrates; Cognition Disorders; gamma- | 2012 |
Axo-axonic structures in the medial prefrontal cortex of the rat: reduction by prenatal exposure to cocaine.
Topics: Animals; Axons; Carrier Proteins; Cell Count; Cocaine; Cognition Disorders; Dopamine Uptake Inhibito | 2003 |
Proton magnetic resonance spectroscopy and cognitive function in pediatric attention-deficit/hyperactive disorder.
Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain Stem; Child; Choline; Cognition | 2004 |
Compulsive behavior and eye blink in Prader-Willi syndrome: neurochemical implications.
Topics: Adolescent; Adult; Blinking; Child; Cognition Disorders; Compulsive Behavior; Dopamine; Female; gamm | 2004 |
Neural synchronization deficits to auditory stimulation in bipolar disorder.
Topics: Acoustic Stimulation; Adult; Auditory Perceptual Disorders; Bipolar Disorder; Cerebral Cortex; Cogni | 2004 |
GABA neurons in the human prefrontal cortex.
Topics: Calbindin 2; Cognition Disorders; gamma-Aminobutyric Acid; Gene Expression; Humans; In Situ Hybridiz | 2004 |
A neuropsychological assessment of phobias in patients with stiff person syndrome.
Topics: Accidental Falls; Adult; Anxiety Disorders; Brain; Brain Chemistry; Cognition Disorders; Female; gam | 2005 |
Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cognition Disorders; Depression; Female | 2006 |
Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Atrophy; Basal Ganglia; Brain; Brain Damage, Chronic; Carbam | 2005 |
Cognitive deficits predict low treatment retention in cocaine dependent patients.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognition Disorders; Cognitive Behavioral Therapy; Cyclohe | 2006 |
Cognitive deficits predict low treatment retention in cocaine dependent patients.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognition Disorders; Cognitive Behavioral Therapy; Cyclohe | 2006 |
Cognitive deficits predict low treatment retention in cocaine dependent patients.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognition Disorders; Cognitive Behavioral Therapy; Cyclohe | 2006 |
Cognitive deficits predict low treatment retention in cocaine dependent patients.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognition Disorders; Cognitive Behavioral Therapy; Cyclohe | 2006 |
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-P | 2005 |
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
Topics: Amines; Amitriptyline; Animals; Cognition Disorders; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2006 |
Behavioral correlates of GABAergic disruption in Alzheimer's disease.
Topics: Affect; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Cognition Disorders; Depressive Diso | 2007 |
Cognitive function impairment in patients with neuropathic pain under standard conditions of care.
Topics: Adult; Aged; Amines; Analgesics; Cognition Disorders; Cohort Studies; Cyclohexanecarboxylic Acids; F | 2007 |
Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat.
Topics: Animals; Behavior, Animal; Cognition Disorders; Conditioning, Operant; Dentate Gyrus; Disease Models | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorde | 2007 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
Cerebellar cognitive affective syndrome associated with topiramate.
Topics: Amines; Anticonvulsants; Carbamazepine; Cerebellar Diseases; Cerebellum; Cognition Disorders; Cycloh | 2008 |
Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits.
Topics: Aging; Animals; Antioxidants; Body Weight; Brain Chemistry; Calcium Radioisotopes; Cognition Disorde | 1998 |
Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspartic Acid; Carotid Stenosis; Cognition Disorders; Corpu | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Effects of antiepileptic drugs on cognition.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Cyclohexanecarboxy | 2001 |
[Neurologic adverse manifestations and complications of ambulatory therapy with psychotropic drugs in the late stages].
Topics: Adult; Aged; Antidepressive Agents; Autonomic Nervous System; Basal Ganglia Diseases; Cognition Diso | 1978 |
[Consciousness disorders in the aged due to therapeutic drugs].
Topics: Aged; Anemia; Cognition Disorders; Consciousness Disorders; Drug Interactions; Flunarizine; gamma-Am | 1990 |